Products
Pre-Made Rozibafusp Alfa Biosimilar, Fusion Protein targeting ICOS fused with human TNFSF13B (tumor necrosis factor (TNF) superfamily member 13B, BAFF, THANK, TALL1, TALL-1, BLYS, BLyS, B cell activating factor, B lymphocyte activator, CD257): Recombinant therapeutic protein targeting AILIM/CD278/CVID1 for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-INN-982
Pre-Made Rozibafusp Alfa Biosimilar, Fusion Protein targeting ICOS fused with human TNFSF13B (tumor necrosis factor (TNF) superfamily member 13B, BAFF, THANK, TALL1, TALL-1, BLYS, BLyS, B cell activating factor, B lymphocyte activator, CD257): Recombinant therapeutic protein targeting AILIM/CD278/CVID1 is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Autoimmune diseases, including systemic lupus erythematosus (SLE), are associated with dysregulated T cell and B cell responses. Rozibafusp alfa is a bispecific molecule targeting T cell and B cell activity through inhibition of the inducible costimulator ligand (ICOSL) and the B cell activating factor (BAFF). Targeting both ICOSL and BAFF will be more effective than single target inhibition in SLE and other autoimmune diseases.
Order information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
| Catalog No. | Package | Price(In USD) | Qty (Quantity) | Sum(In USD) |
|---|---|---|---|---|
| GMP-Bios-INN-982-1mg | 1mg | 3090 | ||
| GMP-Bios-INN-982-10mg | 10mg | Inquiry | ||
| GMP-Bios-INN-982-100mg | 100mg | Inquiry | ||
| GMP-Bios-INN-982-xmg | ≥100mg | Inquiry | ||
| Shipping Cost: | 760.00 | |||
| Total: | ||||
Description
| Products Name (INN Index) | Pre-Made Rozibafusp Alfa Biosimilar, Fusion Protein targeting ICOS fused with human TNFSF13B (tumor necrosis factor (TNF) superfamily member 13B, BAFF, THANK, TALL1, TALL-1, BLYS, BLyS, B cell activating factor, B lymphocyte activator, CD257): Recombinant therapeutic protein targeting AILIM/CD278/CVID1 |
| INN Name | Rozibafusp Alfa |
| Target | ICOS |
| Format | Fusion Protein |
| Derivation | human |
| Species Reactivity | human |
| CH1 Isotype | IgG2 - kappa |
| VD LC | IgG2 - kappa |
| Highest_Clin_Trial (Jan '20) | |
| Est. Status | |
| 100% SI Structure | |
| 99% SI Structure | |
| 95-98% SI Structure | |
| Year Proposed | |
| Year Recommended | |
| Companies | Amgen (Thousand Oaks CA USA) |
| Conditions Approved | |
| Conditions Active | |
| Conditions Discontinued | |
| Development Tech | 0 |
